Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Fineline Cube May 28, 2026
Company Deals

Lantheus Holdings Receives $7 Billion Buyout Offer from Curium Pharma – Radiopharmaceutical Leader’s Alzheimer’s Portfolio Attracts Strategic Interest

Fineline Cube May 28, 2026
Company Deals

Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug – Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment

Fineline Cube May 28, 2026
Company Deals

Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines – World’s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas

Fineline Cube May 28, 2026
Company Deals Drug

Shanghai Pharma Partners with BeOne Medicines on Imdelltra Distribution – Expanding Access to DLL3/CD3 Bispecific T-Cell Engager in China

Fineline Cube May 28, 2026
Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Fineline Cube May 26, 2026
Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Fineline Cube May 28, 2026
Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Fineline Cube May 28, 2026
Company

MicuRx Pharmaceuticals Reports 44% Revenue Growth and Increased R&D Spending in 2024 H1

Fineline Cube Sep 3, 2024

SHANGHAI—MicuRx Pharmaceuticals (SHA: 688373), a Shanghai-based developer of antibacterial drugs, has released its financial report...

Company Drug

Shandong Buchang Pharmaceuticals’ rhEPO-Fc for CKD Anemia Accepted for Review by China’s CDE

Fineline Cube Sep 3, 2024

BEIJING—The Center for Drug Evaluation (CDE) in China has accepted the market filing for a...

Company Drug

Biocon Biologics Resolves Patent Dispute with J&J, Secures Market Entry for Biosimilar Stelara

Fineline Cube Sep 2, 2024

Biocon Biologics Ltd, the biosimilars division of Indian pharmaceutical company Biocon Ltd (BOM: 532523, NSE:...

Company Drug

Zuellig Pharma Partners with Regeneron for Libtayo Launch in South Korea and Taiwan

Fineline Cube Sep 2, 2024

Singapore-headquartered Zuellig Pharma, a leading healthcare solutions provider, has entered into an agreement with US...

Company Drug

HutchMed Halts China Filing for Gastric Cancer Drug Fruquintinib Following Regulatory Feedback

Fineline Cube Sep 2, 2024

HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013), a China-based biopharmaceutical company, has announced the withdrawal...

Company Drug

Novo Nordisk to Resubmit Wegovy Heart Failure Application with Updated Clinical Data

Fineline Cube Sep 2, 2024

Denmark’s pharmaceutical giant, Novo Nordisk (NYSE: NVO), has reported significant findings on the efficacy of...

Company Drug

AccurEdit Therapeutics’ Gene-Editing Drug ART001 Clears FDA Hurdle for US Clinical Trials

Fineline Cube Sep 2, 2024

SUZHOU—AccurEdit Therapeutics (Suzhou) Co., Ltd, a leading Chinese specialist in gene editing therapies, has announced...

Company Deals

Hybio Pharmaceutical Inks Licensing Deal with Mullan Pharmaceutical for Liraglutide Biosimilar

Fineline Cube Sep 2, 2024

BEIJING—Hybio Pharmaceutical Co., Ltd (SHE: 300199), a Chinese biopharmaceutical company, has entered into a licensing...

Company Deals

Allist Pharmaceuticals Acquires Jacobio’s G12C Inhibitor and SHP2 Inhibitor Rights for Greater China Region

Fineline Cube Sep 2, 2024

SHANGHAI—Allist Pharmaceuticals Co., Ltd, a Shanghai-based biotech company, has entered into a licensing agreement with...

Company Deals R&D

Baheal Pharmaceutical Group to Establish R&D Center for Myocardial Repair with CAMS Fuwai Hospital

Fineline Cube Sep 2, 2024

BEIJING—Baheal Pharmaceutical Group, a leading healthcare services and distribution company in China, is venturing into...

Company Drug

Bio-Thera Solutions’ BAT2406 Biosimilar Gets Green Light for Clinical Trials in China

Fineline Cube Sep 2, 2024

GUANGZHOU—Bio-Thera Solutions (SHA: 688177), a leading biopharmaceutical company based in Guangzhou, has received approval from...

Policy / Regulatory

NMPA Unveils 82nd Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Sep 2, 2024

The National Medical Products Administration (NMPA) has announced the release of the 82nd batch of...

Policy / Regulatory

Hainan Province Unveils Ambitious Three-Year Plan for Digital Health Innovation and Economy Expansion

Fineline Cube Sep 2, 2024

HAIKOU—The People’s Government of Hainan Province has unveiled the “Hainan Province’s Three Year Action Plan...

Policy / Regulatory

China Expands Medical Insurance Coverage to Include Assisted Reproductive Technology in 19 Regions

Fineline Cube Sep 2, 2024

BEIJING—As of September 1, 2024, a total of 19 provinces, municipalities, and the Xinjiang Production...

Company

BioAge Labs Taps Former GSK CEO Jean-Pierre Garnier as Chairman

Fineline Cube Sep 2, 2024

NEW YORK—BioAge Labs, a US-based biotechnology company specializing in anti-aging therapies, has announced the appointment...

Company Policy / Regulatory

China’s NMPA Suspends Dr. Reddy’s Atomoxetine Imports Amid Quality Concerns

Fineline Cube Sep 2, 2024

BEIJING—The National Medical Products Administration (NMPA) has issued a notification to immediately suspend the import,...

Company

Roche Diagnostics to Double Down on China with RMB 3 Billion Suzhou Plant Expansion

Fineline Cube Sep 2, 2024

SUZHOU—Roche Diagnostics, the Swiss healthcare giant, has entered into a new investment agreement with the...

Company Deals

WuXi Biologics to Acquire Full Control of Vaccine Contract Services Subsidiary for $108.5 Million

Fineline Cube Sep 2, 2024

HONG KONG—WuXi Biologics (HKG: 2269), a leading global open biopharmaceutical technology platform company, has announced...

Company Deals

Tiantan Biological to Acquire Wuhan Zhongyuan Ruide for $185 Million, Expanding Plasma Resources

Fineline Cube Sep 2, 2024

BEIJING—Beijing Tiantan Biological Products Co., Ltd (Tiantan Biological, SHA: 600161) has announced that its subsidiary,...

Company

Junshi Biosciences Logs 17.37% Revenue Growth in 2024H1, Fueled by Loqtorzi Sales Surge

Fineline Cube Sep 2, 2024

SHANGHAI—Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced its financial results for...

Posts pagination

1 … 311 312 313 … 673

Recent updates

  • LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases
  • Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy
  • J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market
  • Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile
  • Dizal Pharmaceutical’s Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC – Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Company

J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market

Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.